Worth Watching Stocks: Netflix, Inc. (NFLX), CenturyLink, Inc. (CTL), Sarepta Therapeutics, Inc. (SRPT)

Netflix, Inc. (NFLX) saw its value increase by 0.47% as the stock gained $0.61 to finish the day at a closing price of $130.5. The stock was lighter in trading and has fluctuated between $79.95-$133.88 per share for the past year. The shares are up by 29.73% in the past three months and up by 35.33% over the past six months. It is currently trading 3.1% above its 20 day moving average and 6.58% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $124.35 a share over the next twelve months. The current relative strength index (RSI) reading is 64.43.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Netflix, Inc., an Internet television network, engages in the Internet delivery of television (TV) shows and movies on various Internet-connected screens. The company operates in three segments: Domestic streaming, International streaming and Domestic DVD. It offer members with the ability to receive TV shows and movies streaming content, including original series, documentaries, and feature films through a host of Internet-connected screens, such as TVs, digital video players, TV set-top boxes, and mobile devices. The company also provides DVDs-by-mail membership services. As of October 17, 2016, it served approximately 86 million streaming members in 190 countries. Netflix, Inc. was founded in 1997 and is headquartered in Los Gatos, California.

CenturyLink, Inc. (CTL) shares were up in last trading by 0.16% to $25.24. It experienced lighter than average volume on day. The stock decreased in value by almost -0.94% over the past week and grew 4.64% in the past month. It is currently trading 3.98% above its 50 day moving average and -6.42% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -22.89% decrease in value from its one year high of $33.45. The RSI indicator value of 63.24, lead us to believe that it is a hold for now.

CenturyLink, Inc. provides various communications services to residential, business, wholesale, and governmental customers in the United States. It operates through two segments, Business and Consumer. The company offers high-speed Internet services, which allow customers to connect to the Internet through their existing telephone lines or fiber-optic cables; multi-protocol label switching, a data networking technology to support real-time voice and video; and private line services for the transmission of data between sites. It also provides Ethernet services, including point-to-point and multi-point equipment configurations that facilitate data transmissions across metropolitan areas and wide area networks (WAN); colocation services that enable its customers to install their own information technology (IT) equipment; and managed hosting services comprising cloud and traditional computing, application management, back-up, storage, and other services. In addition, the company offers video entertainment services and satellite digital television; Voice over Internet Protocol, a real-time, two-way voice communication service; and managed services that consist of network, hosting, cloud, and IT services. Further, it provides local calling, long-distance voice, integrated services digital network, WAN, and switched access services; and data integration, which includes the sale of telecommunications equipment and providing network management, installation, and maintenance of data equipment, and the building of proprietary fiber-optic broadband networks. Additionally, the company leases and subleases space in its office buildings, warehouses, and other properties. As of December 31, 2015, it served approximately 6 million high-speed Internet subscribers and 285 thousand television subscribers; and operated 59 data centers in North America, Europe, and Asia. CenturyLink, Inc. was founded in 1968 and is headquartered in Monroe, Louisiana.

Sarepta Therapeutics, Inc. (SRPT) opening the day at $38.24. The company has seen its stock increase in value by 29.6% so far this year. The stock was down close to -6.18% on active volume in last trading session and closed at $35.55 per share. After the recent fall, the stock is currently holding -44.22% below its 52 week high of $63.73 and 344.37% above its 12-month low of $8. The shares are down by over -33.95% in the last three months, and the RSI indicator value of 59.51 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

 

Investor’s Alert: Merck & Co., Inc. (MRK), Sarepta Therapeutics, Inc. (SRPT), Kinder Morgan, Inc. (KMI)

Merck & Co., Inc. (MRK) failed to extend gains with the stock declining -1.93% or $-1.18 to close the day at $59.92 on higher than average trading volume of 15.15M shares, compared to its three month average trading volume of 10.8M. The Kenilworth New Jersey 07033 based company has been underperforming the drug manufacturers – major companies by -5.4901% for last three months and its recent losses have trimmed gains to 1.78% YTD, versus the drug manufacturers – major industry which is up 2.24% for the same period. The RSI of 44.33 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Sarepta Therapeutics, Inc. (SRPT) had a light trading with around 14.82M shares changing hands compared to its three month average trading volume of 2.39M. The stock traded at the price of $37.89 with 21.21% change on the day. The Cambridge Massachusetts 02142 based company is currently trading 373.62% above its 52 week low of $8 and -40.55% below its 52 week high of $63.73. Both the RSI indicator and target price of 67.47 and $64.33 respectively, lead us to believe that it should be put on hold over the coming weeks.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Kinder Morgan, Inc. (KMI) traded within a range of $21.49 to $21.8 after opening the day at $21.74. The company has seen its stock increase in value by 4.15% so far this year. The stock was down close to -0.32% on active volume in last trading session and closed at $21.57 per share. After the recent fall, the stock is currently holding -7.11% below its 52 week high of $23.36 and 98.03% above its 12-month low of $11.2. The shares are up by over 1.3% in the last three months, and the RSI indicator value of 54.43 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Kinder Morgan, Inc. operates as an energy infrastructure company in North America. It operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments. The Natural Gas Pipelines segment owns and operates interstate and intrastate natural gas pipeline and storage systems; natural gas and crude oil gathering systems, and natural gas processing and treating facilities; natural gas liquids fractionation facilities and transportation systems; and liquefied natural gas facilities. The CO2 segment produces, transports, and markets CO2 for use in enhanced oil recovery projects; and owns interests in oil-producing fields, gas processing plants, and crude oil pipelines in the Permian Basin region of West Texas. The Terminals segment owns and operates liquids and bulk terminals that transload and store refined petroleum products, crude oil, and condensate, as well as bulk products, including coal, petroleum coke, cement, alumina, salt, and other bulk chemicals; and owns and operates tankers. The Products Pipelines segment owns and operates refined petroleum products, and crude oil and condensate pipelines; and associated product terminals and petroleum pipeline transmix facilities. The Kinder Morgan Canada segment owns and operates Trans Mountain pipeline system that transports crude oil and refined petroleum products from Edmonton, Alberta, and Canada to marketing terminals and refineries in British Columbia, Canada, and Washington; and jet fuel aviation turbine fuel pipeline that serves the Vancouver (Canada) International Airport. The Other segment includes various physical natural gas contracts with power plants. Kinder Morgan, Inc. owns interests in or operates approximately 84,000 miles of pipelines and 180 terminals. The company was formerly known as Kinder Morgan Holdco LLC and changed its name to Kinder Morgan, Inc. in February 2011. Kinder Morgan, Inc. was founded in 1936 and is headquartered in Houston, Texas.

 

Stocks Buzz: Sarepta Therapeutics, Inc. (SRPT), SM Energy Company (SM), Immunomedics, Inc. (IMMU)

Sarepta Therapeutics, Inc. (SRPT) continued its upward trend with the stock climbing 3.92% or $1.18 to close the day at $31.26 on active trading volume of 2.72M shares, compared to its three month average trading volume of 2.49M. The Cambridge Massachusetts 02142 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -13%, compared to the industry which has advanced 0.02% over the same period. With RSI of 51.01, the stock should still continue to rise and get closer to its one year target estimate of $64.33, making it a hold for now.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

SM Energy Company (SM) retreated with the stock falling -3.55% or $-1.27 to close at $34.49 on light trading volume of 2.71M compared its three months average trading volume of 2.87M. The Denver Colorado 80203 based company operating under the Independent Oil & Gas industry has been trending up for the last 52 weeks, with the shares price now 113.72% up for the period and up by 0.03% so far this year. With price target of $46.83 and a 395.01% rebound from 52-week low, SM Energy Company has plenty of upside potential, making it a hold with a view buy.

SM Energy Company, an independent energy company, engages in the acquisition, exploration, development, and production of crude oil and condensate, natural gas, and natural gas liquids in onshore North America. It primarily has operations in the South Texas and Gulf Coast region, which focuses primarily on Eagle Ford shale program; Rocky Mountain region comprising the Bakken and Three Forks formations in the North Dakota; and Permian region covering western Texas and southeastern New Mexico. As of December 31, 2015, the company had 471.3 million barrels of oil equivalent of estimated proved reserves; and working interests in 872 net productive oil wells and 653 net productive gas wells. The company was formerly known as St. Mary Land & Exploration Company and changed its name to SM Energy Company in May 2010. SM Energy Company was founded in 1908 and is headquartered in Denver, Colorado.

Immunomedics, Inc. (IMMU) continued its downward trend with the stock declining -6.7% or $-0.25 to close the day at $3.48 on higher than average trading volume of 2.7M shares, compared to its three month average trading volume of 1.67M. The Morris Plains New Jersey 07950 based company has been outperforming the biotechnology companies by 34.8048% for last three months and its recent gains have offset losses to -5.18% YTD, versus the biotechnology industry which is up 3.69% for the same period. The RSI of 49.37 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and epratuzumab, a humanized antibody that targets CD22, an antigen found on the surface of B lymphocytes. Its early-stage products include IMMU-114, a novel humanized antibody for the treatment of patients with B-cell and other cancers; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is present on various hematological tumors and solid cancers; Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma and autoimmune diseases; and Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

 

3 Stocks to Watch For: Las Vegas Sands Corp. (LVS), Sarepta Therapeutics, Inc. (SRPT), Ciena Corporation (CIEN)

Las Vegas Sands Corp. (LVS) saw its value increase by 0.71% as the stock gained $0.39 to finish the day at a closing price of $55.47. The stock was lighter in trading and has fluctuated between $34.88-$63.38 per share for the past year. The shares, which traded within a range of $54.58 to $55.63 during the day, are down by -4.46% in the past three months and up by 28.92% over the past six months. It is currently trading 0.61% above its 20 day moving average and -3.49% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $60.76 a share over the next twelve months. The current relative strength index (RSI) reading is 48.35.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Las Vegas Sands Corp., together with its subsidiaries, develops, owns, and operates integrated resorts in Asia and the United States. It owns and operates The Venetian Macao Resort Hotel, Sands Cotai Central, the Four Seasons Hotel Macao, Cotai Strip, the Plaza Casino, and the Sands Macao in Macao, the People’s Republic of China; and iconic Marina Bay Sands in Singapore. The company also owns and operates The Venetian Resort Hotel Casino, The Palazzo Resort Hotel Casino, and Five-Diamond luxury resorts on the Las Vegas Strip; Sands Expo and Convention Center in Las Vegas, Nevada; and the Sands Casino Resort Bethlehem in Bethlehem, Pennsylvania. Its integrated resorts include accommodations, gaming, entertainment and retail, convention and exhibition facilities, celebrity chef restaurants, and other amenities. Las Vegas Sands Corp. was founded in 1988 and is based in Las Vegas, Nevada.

Sarepta Therapeutics, Inc. (SRPT) shares were up in last trading by 1.9% to $30.08. It experienced higher than average volume on day. The stock increased in value by almost 8.87% over the past week and fell -13.61% in the past month. It is currently trading -14.08% below its 50 day moving average and 2.9% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -52.8% decrease in value from its one year high of $63.73. The RSI indicator value of 45.37, lead us to believe that it is a hold for now.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Ciena Corporation (CIEN) traded within a range of $23.87 to $24.37 after opening the day at $24.33. The company has seen its stock decrease in value by -0.86% so far this year. The stock was down close to -0.41% on active volume in last trading session and closed at $24.2 per share. After the recent fall, the stock is currently holding -3.93% below its 52 week high of $25.19 and 54.93% above its 12-month low of $15.62. The shares are up by over 6.75% in the last three months, and the RSI indicator value of 57.02 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company’s Networking Platforms segment offers hardware networking solutions optimized for the convergence of coherent optical transport, optical transport network switching, and packet switching. Its products include 6500 Packet-Optical Platform and the 5430 Reconfigurable Switching System, Waveserver stackable interconnect system, CoreDirector Multiservice Optical Switches, and OTN configuration for the 5410 Reconfigurable Switching System, as well as Z-Series Packet-Optical Platform; 3000 family of service delivery switches and service aggregation switches, and the 5000 family of service aggregation switches, as well as 8700 Packetwave Platform and the Ethernet packet configuration for the 5410 Service Aggregation Switch; and 4200 Advanced Services Platform, Corestream 5100/5200 Advanced Services Platform, Common Photonic Layer, and 6100 Multiservice Optical Platform. This segment also sells operating system software and enhanced software features embedded in each of these products. The company’s Software and Software-Related Services segment offers network management solutions, including the OneControl Unified Management System, ON-Center Network & Service Management Suite, Ethernet Services Manager, Optical Suite Release, and Planet Operate; and Blue Planet network virtualization, service orchestration, and network management software platform, as well as related installation, support, and consulting services. Its Global Services segment provides consulting and network design, installation and deployment, maintenance support, and training services. The company sells its products through direct and indirect sales channels to network operators. Ciena Corporation was founded in 1992 and is headquartered in Hanover, Maryland.

 

Momentum Stocks: Baxter International Inc. (BAX), Senior Housing Properties Trust (SNH), Sarepta Therapeutics, Inc. (SRPT)

Baxter International Inc. (BAX) grew with the stock adding 0.67% or $0.3 to close at $45.05 on light trading volume of 2.34M compared its three months average trading volume of 4.04M. The Deerfield Illinois 60015 based company operating under the Medical Instruments & Supplies industry has been trending up for the last 52 weeks, with the shares price now 21.83% up for the period and up by 1.6% so far this year. With price target of $53.25 and a 33.81% rebound from 52-week low, Baxter International Inc. has plenty of upside potential, making it a hold with a view buy.

Baxter International Inc. provides a portfolio of renal and hospital products. Its Renal segment provides products and services to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis (HD), home HD, continuous renal replacement therapy, and additional dialysis services. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and by patients at home under physician supervision. Baxter International Inc. offers its products through direct sales force, independent distributors or sales agents, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. The company was founded in 1931 and is headquartered in Deerfield, Illinois.

Senior Housing Properties Trust (SNH) had a active trading with around 2.34M shares changing hands compared to its three month average trading volume of 2.31M. The stock traded at the price of $19.41 with 0.73% change on the day. The Newton Massachusetts 02458 based company is currently trading 46.61% above its 52 week low of $13.53 and -18.62% below its 52 week high of $23.85. Both the RSI indicator and target price of  and $20.64 respectively, lead us to believe that it could rise over the coming weeks.

Senior Housing Properties Trust, a real estate investment trust (REIT), primarily invests in senior housing properties in the United States. The trust invests in hospitals, nursing homes, senior apartments, independent living properties, and assisted living properties. As of September 30, 2005, it owned 184 properties, including 85 assisted living facilities, 61 skilled nursing facilities, 36 independent living communities, and 2 hospitals. The trust elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code. As a REIT, it would not be subject to federal income tax, if it distributes at least 90% of its REIT taxable income to its shareholders. Senior Housing Properties Trust was organized in 1998 and is based in Newton, Massachusetts.

Sarepta Therapeutics, Inc. (SRPT) saw its value increase by 0.96% as the stock gained $0.28 to finish the day at a closing price of $29.52. The stock was lighter in trading and has fluctuated between $8-$63.73 per share for the past year. The shares are down by -52.65% in the past three months and up by 41.11% over the past six months. It is currently trading -2.84% below its 20 day moving average and -16.51% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $65.56 a share over the next twelve months. The current relative strength index (RSI) reading is 42.53.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

 

Investor’s Watch List: Sarepta Therapeutics, Inc. (SRPT), Endologix, Inc. (ELGX), Sears Holdings Corporation (SHLD)

Sarepta Therapeutics, Inc. (SRPT) had a active trading with around 2.99M shares changing hands compared to its three month average trading volume of 2.45M. The stock traded at the price of $29.24 with 4.73% change on the day. The Cambridge Massachusetts 02142 based company is currently trading 265.5% above its 52 week low of $8 and -54.12% below its 52 week high of $63.73. Both the RSI indicator and target price of 42.38 and $65.56 respectively, lead us to believe that it should be put on hold over the coming weeks.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Endologix, Inc. (ELGX) managed to rebound with the stock climbing 4.9% or $0.27 to close the day at $5.78 on active trading volume of 2.98M shares, compared to its three month average trading volume of 2.08M. The Irvine California 92618 based company has been underperforming the medical instruments & supplies group over the past 52 weeks, with the stock losing -42.03%, compared to the industry which has advanced 14.15% over the same period. With RSI of 38.07, the stock should still continue to rise and get closer to its one year target estimate of $9.18, making it a hold for now.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular repair (EVAR) products, including EVAR stent graft and catheter delivery system under the Powerlink, IntuiTrak, AFX, and VELA Proximal Endograft brand names. It also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which attach to the main body of its EVAR device, allowing physicians to customize it to fit the patient’s anatomy; and accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Sears Holdings Corporation (SHLD) shares were up in last trading by 6.58% to $10.36. It experienced higher than average volume on day. The stock increased in value by almost 24.97% over the past week and fell -17.19% in the past month. It is currently trading -9.01% below its 50 day moving average and -21.94% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -49.41% decrease in value from its one year high of $19.54. The RSI indicator value of 50.27, lead us to believe that it is a hold for now.

Sears Holdings Corporation operates as a retailer in the United States. It operates in two segments, Kmart and Sears Domestic. The Kmart segment operates retail stores that offer a range of products, including consumer electronics, seasonal merchandise, outdoor living, toys, lawn and garden equipment, food and consumables, and apparel; and in-store pharmacies. It provides merchandise under the Jaclyn Smith, Joe Boxer, and Alphaline labels; Sears brand products, such as Kenmore, Craftsman, and DieHard; and Kenmore-branded products. As of October 31, 2015, this segment operated approximately 952 Kmart stores. The Sears Domestic segment operates stores that provide appliances, consumer electronics/connected solutions, tools, sporting goods, outdoor living, lawn and garden equipment, apparel, footwear, jewelry, and accessories, as well as automotive services and products, such as tires, batteries, and home fashion products. It also offers appliances and services to commercial customers in the single-family residential construction/remodel, property management, multi-family new construction, and government/military sectors; appliance and plumbing fixtures to architects, designers, and new construction or remodeling customers; parts and repair services for appliances, lawn and garden equipment, consumer electronics, floor care products, and heating and cooling systems; and home improvement services, as well as protection agreements and product installation services. This segment provides merchandise under the Kenmore, Craftsman, DieHard, Covington, Canyon River Blues, Metaphor, Outdoor Life, Structure, and Apostrophe brands, as well as under the Roadhandler, Ty Pennington Style, and Alphaline brands. As of October 31, 2015, this segment operated 735 Sears stores. Sears Holdings Corporation was founded in 1899 and is based in Hoffman Estates, Illinois.

 

Momentum Stocks in Focus: Sarepta Therapeutics, Inc. (SRPT), Carnival Corporation (CCL), KKR & Co. L.P. (KKR)

Sarepta Therapeutics, Inc. (SRPT) continued its downward trend with the stock declining -2.61% or $-0.74 to close the day at $27.63 on light trading volume of 1.65M shares, compared to its three month average trading volume of 2.49M. The Cambridge Massachusetts 02142 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -28.55%, compared to the industry which has dropped -6.34% over the same period. With RSI of 32.79, the stock should still continue to rise and get closer to its one year target estimate of $65.56, making it a hold for now.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Carnival Corporation (CCL) retreated with the stock falling -0.38% or $-0.2 to close at $51.99 on light trading volume of 1.64M compared its three months average trading volume of 3.78M. The Miami Florida 33178 based company operating under the Resorts & Casinos industry has been trending down for the last 52 weeks, with the shares price now -2.88% down for the period and down by -1.88% so far this year. With price target of $56.64 and a 31.92% rebound from 52-week low, Carnival Corporation has plenty of upside potential, making it a hold with a view buy.

Carnival Corporation operates as a leisure travel and cruise company in North America, Europe, Australia, and Asia. It offers cruises under the Carnival Cruise Line, Princess Cruises, Holland America Line, and Seabourn brands in North America; and Costa, AIDA, P&O Cruises (UK), Cunard, and P&O Cruises (Australia) brands in Europe, Australia, and Asia. The company operates 99 cruise ships. It also owns Holland America Princess Alaska Tours, a tour company in Alaska and the Canadian Yukon, which owns and operates 11 hotels or lodges, approximately 300 motor coaches, and 20 glass-domed railcars. In addition, the company is involved in the leasing of cruise ships. It sells its cruises primarily through travel agents and tour operators. Carnival Corporation was incorporated in 1972 and is headquartered in Miami, Florida. Carnival Corporation operates as a subsidiary of Carnival Corporation & Plc.

KKR & Co. L.P. (KKR) continued its downward trend with the stock declining -0.9% or $-0.14 to close the day at $15.47 on lower than average trading volume of 1.64M shares, compared to its three month average trading volume of 2.78M. The New York New York 10019 based company has been outperforming the asset management companies by 11.2648% for last three months and its recent gains have pushed the stock slightly up 4.07% YTD, versus the asset management industry which is up 8.73% for the same period. The RSI of 42.31 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

KKR & Co. L.P. is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, management buyouts, credit special situations, growth equity, mature, mezzanine, distressed, and middle market investments. The firm considers investments in all industries with a focus on software, security, semiconductors, consumer electronics, internet of things (iot), internet, information services, content, technology and hardware, energy and infrastructure, real estate, services industry with a focus on business services, intelligence, industry-leading franchises and companies in natural resource, containers and packaging, agriculture, airports, ports, forestry, electric utilities, textiles, apparel and luxury goods, household durables, digital media, insurance, brokerage houses, non-durable goods distribution, supermarket retailing, grocery stores, food, beverage, and tobacco, hospitals, entertainment venues and production companies, publishing, printing services, capital goods, financial services, specialized finance, pipelines, and renewable energy. In energy and infrastructure, it focuses on the Upstream Oil and Gas and Equipment and Services verticals. In real estate, the firm seeks to invest in private and public real estate securities including property-level equity, debt and special situations transactions and businesses with significant real estate holdings, and oil and natural gas properties. The firm also invests in asset services sector that encompasses a broad array of B2B, B2C and B2G services verticals including asset-based, transport, logistics, leisure/hospitality, resource and utility support, infra-like, mission-critical, and environmental services. Within Americas, the firm prefers to invest in consumer products; chemicals, metals and mining; energy and natural resources; financial services; healthcare; industrials; media and communications; retail; and technology. Within Europe, the firm invests in consumer and retail; energy; financial services; health care; industrials and chemicals; media and digital; and telecom and technologies. Within Asia, it invests in consumer products; energy and resources; financial services; healthcare; industrials; logistics; media and telecom; retail; real estate; and technology. The firm seeks to invest in mid to high-end residential developments, but can invest in other projects throughout Mainland China through outright ownership, joint ventures, and merger. It invests globally with a focus on Australia, emerging and developed Asia, Middle East and Africa, Nordic, Southeast Asia, Asia Pacific, Ireland, Hong Kong, Japan, Taiwan, India, Vietnam, Indonesia, France, Germany, Netherlands, United Kingdom, Caribbean, Mexico, South America, North America, Brazil, Latin America, Korea, and United States of America. In the United States and Europe, the firm focuses on buyouts of large, publicly traded companies. It seeks to invest $30 million to $717 million in companies with enterprise values between $500 million to $2389 million. The firm prefers to invest in a range of debt and public equity investing and may co-invest. It seeks a board seat in its portfolio companies and a controlling ownership of a company or a strategic minority positions. The firm may acquire minority equity interests, particularly when making private equity investments in Asia or sponsoring investments as part of a large investor consortium. The firm typically holds its investment for a period of five to seven years and more and exits through initial public offerings, secondary offerings, and sales to strategic buyers. KKR & Co. L.P. was founded in 1976 and is based in New York, New York with additional offices across North America, Europe, Australia, and Asia.

 

Traders Recap: EXCO Resources, Inc. (XCO), Sarepta Therapeutics, Inc. (SRPT), The Goldman Sachs Group, Inc. (GS)

EXCO Resources, Inc. (XCO) continued its downward trend with the stock declining -2.08% or $-0.02 to close the day at $0.95 on higher than average trading volume of 2.23M shares, compared to its three month average trading volume of 1.38M. The Dallas Texas 75251 based company has been outperforming the independent oil & gas companies by -7.9145% for last three months and its recent losses have pulled the stock down -23.4% YTD, versus the independent oil & gas industry which is up 33.88% for the same period. The RSI of 32.79 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States. The company holds interests in approximately 83,800 net acres located in the Haynesville and Bossier shales of East Texas and North Louisiana; approximately 65,800 net acres situated in the Eagle Ford shale of South Texas; and approximately 137,400 net acres of prospective area located in the Marcellus shale of the Appalachian basin. As of December 31, 2015, it had proved reserves of approximately 907.3 billion cubic feet equivalent of oil and gas; and operated 6,380 gross wells. The company was founded in 1955 and is based in Dallas, Texas.

Sarepta Therapeutics, Inc. (SRPT) had a light trading with around 2.19M shares changing hands compared to its three month average trading volume of 2.79M. The stock traded at the price of $29.9 with 6.18% change on the day. The Cambridge Massachusetts 02142 based company is currently trading 273.75% above its 52 week low of $8 and -53.08% below its 52 week high of $63.73. Both the RSI indicator and target price of 36.45 and $65.56 respectively, lead us to believe that it should be put on hold over the coming weeks.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

The Goldman Sachs Group, Inc. (GS) traded within a range of $238.91 to $241.9 after opening the day at $239.54. The company has seen its stock increase in value by 35.78% so far this year. The stock was up close to 0.35% on light volume in last trading session and closed at $240.97 per share. After the recent gain, the stock is currently holding -1.87% below its 52 week high of $245.57 and 75.99% above its 12-month low of $138.2. The shares are up by over 49.69% in the last three months, and the RSI indicator value of 71.28 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

The Goldman Sachs Group, Inc. operates as an investment banking, securities, and investment management company worldwide. It operates through four segments: Investment Banking, Institutional Client Services, Investing & Lending, and Investment Management. The Investment Banking segment provides financial advisory services, such as strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, spin-offs, and risk management; and underwriting services, including public offerings and private placements of various securities and other financial instruments, as well as derivative transactions entered into with public and private sector clients. The Institutional Client Services segment is involved in client execution activities related to making markets in interest rate products, credit products, mortgages, currencies, commodities, and equities; and provides securities services, such as financing, securities lending, and other prime brokerage services, as well as markets in and clears client transactions on primary stock, options, and futures exchanges. The Investing & Lending segment invests in and originates longer-term loans to provide financing to clients; and makes investments in debt securities and loans, public and private equity securities, and real estate entities. The Investment Management segment offers investment management products and services; and wealth advisory services, including portfolio management and financial counseling, and brokerage and other transaction services. The company serves corporations, financial institutions, governments, and individuals. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

 

Stocks In Action: Sarepta Therapeutics, Inc. (SRPT), American International Group, Inc. (AIG), McDonald’s Corporation (MCD)

Sarepta Therapeutics, Inc. (SRPT) traded within a range of $28.08 to $31.2 after opening the day at $30.72. The company has seen its stock decrease in value by -27.01% so far this year. The stock was down close to -4.51% on active volume in last trading session and closed at $28.16 per share. After the recent fall, the stock is currently holding -55.81% below its 52 week high of $63.73 and 252% above its 12-month low of $8. The shares are down by over -51.31% in the last three months, and the RSI indicator value of 27.45 is bullish. They are not pointing to a rebound in the stock. We should get in as it looks to have found a bottom.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

American International Group, Inc. (AIG) failed to extend gains with the stock declining -0.65% or $-0.43 to close the day at $66.23 on light trading volume of 3.04M shares, compared to its three month average trading volume of 6.31M. The New York New York 10038 based company has been outperforming the property & casualty insurance group over the past 52 weeks, with the stock gaining 10.28%, compared to the industry which has advanced 21.24% over the same period. With RSI of 64.94, the stock should still continue to rise and get closer to its one year target estimate of $68.31, making it a hold for now.

American International Group, Inc. provides insurance products and services for commercial, institutional, and individual customers in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. The company operates through two segments, Commercial Insurance and Consumer Insurance. The company’s Commercial Insurance segment offers general liability, commercial automobile liability, workers’ compensation, excess casualty, and crisis management causality insurance products, as well as various risk-sharing and other customized structured programs; commercial, industrial, and energy-related property insurance products; aerospace, environmental, political risk, trade credit, surety, and marine insurance products; various insurance products for small and medium sized enterprises; and professional liability insurance products. It also provides mortgage guaranty insurance; stable value wrap products, and structured settlement and terminal funding annuities; and corporate- and bank-owned life insurance and guaranteed investment contracts. This segment sells its products through independent retail and wholesale brokers, agency network, specialized marketing and consulting firms, and structured settlement brokers. Its Consumer Insurance segment offers retirement products, such as fixed annuities, and immediate and deferred income annuities; variable and fixed index annuities; and mutual funds, and plan administrative and compliance services. This segment’s products also include term and whole life, cancer, and critical illness insurance products; personal accident and supplemental health products; travel insurance products and services; automobile and homeowners, and extended warranty insurance; and identity theft and credit card protection products. It sells its products through agents, direct marketing, independent marketing organizations, financial advisors, banks, wirehouses, and broker-dealers. The company was founded in 1919 and is based in New York, New York.

McDonald’s Corporation (MCD) gained $0.54 to close the day at a new closing price of $123.72, a 0.44% increase in value from its previous closing price that moved the stock 13.15% above its 52 week low of $110.33. A total of 3.04M shares exchanged hands during the day compared with its three month average trading volume of 4.39M. The stock, which fluctuated between $123.09 and $124 during the day, currently situated -4.08% below its 52 week high. The stock is up by 4.17% in the past one month and up by 6.41% over the past three months. With a one year target estimate of $127.76 and RSI of 74.08, the stock still has upside potential, making it a sell for now.

McDonald’s Corporation operates and franchises McDonald’s restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, and Latin America. The company’s restaurants offer various food products, soft drinks, coffee, and other beverages. As of December 31, 2015, it operated 36,525 restaurants, including 30,081 franchised restaurants comprising 21,147 franchised to conventional franchisees, 5,529 licensed to developmental licensees, and 3,405 licensed to foreign affiliates; and 6,444 company-operated restaurants. The company was founded in 1940 and is based in Oak Brook, Illinois.

 

Stocks Trend Analysis: Starwood Property Trust, Inc. (STWD), Comerica Incorporated (CMA), Sarepta Therapeutics, Inc. (SRPT)

Starwood Property Trust, Inc. (STWD) continued its downward trend with the stock declining -0.13% or $-0.03 to close the day at $22.28 on active trading volume of 3.49M shares, compared to its three month average trading volume of 2.38M. The Greenwich Connecticut 06830 based company has been outperforming the reit – diversified group over the past 52 weeks, with the stock gaining 20.67%, compared to the industry which has advanced 15.82% over the same period. With RSI of 51.73, the stock should still continue to rise and get closer to its one year target estimate of $23.86, making it a hold for now.

Starwood Property Trust, Inc. originates, acquires, finances, and manages commercial mortgage loans, other commercial real estate debt investments, commercial mortgage-backed securities, and other commercial real estate- investments in the United States and Europe. It operates through three segments: Real Estate Lending, Real Estate Investing and Servicing, and Real Estate Property. The company qualifies as a real estate investment trust for federal income tax purposes and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. Starwood Property Trust, Inc. was founded in 2009 and is headquartered in Greenwich, Connecticut.

Comerica Incorporated (CMA) retreated with the stock falling -0.75% or $-0.51 to close at $67.53 on active trading volume of 3.46M compared its three months average trading volume of 2.19M. The Dallas Texas 75201 based company operating under the Money Center Banks industry has been trending up for the last 52 weeks, with the shares price now 60.22% up for the period and up by 64.55% so far this year. With price target of $60.86 and a 125.83% rebound from 52-week low, Comerica Incorporated has plenty of upside potential, making it a hold with a view buy.

Comerica Incorporated, through its subsidiaries, provides various financial products and services. It operates through three segments: Business Bank, Retail Bank, and Wealth Management. The Business Bank segment offers various products and services, such as commercial loans and lines of credit, deposits, cash management, capital market products, international trade finance, letters of credit, foreign exchange management services, and loan syndication services to middle market businesses, multinational corporations, and governmental entities. The Retail Bank segment provides small business banking and personal financial services, including consumer lending, consumer deposit gathering, and mortgage loan origination. This segment also offers a range of consumer products consisting of deposit accounts, installment loans, credit cards, student loans, home equity lines of credit, and residential mortgage loans. The Wealth Management segment provides products and services comprising fiduciary services, private banking, retirement services, investment management and advisory services, and investment banking and brokerage services. This segment also sells annuity products, as well as life, disability, and long-term care insurance products. The company operates in Texas, California, and Michigan, as well as in Arizona and Florida, the United States; Canada; and Mexico. Comerica Incorporated was founded in 1849 and is headquartered in Dallas, Texas.

Sarepta Therapeutics, Inc. (SRPT) failed to extend gains with the stock declining -5.78% or $-1.84 to close the day at $29.98 on lower than average trading volume of 3.46M shares, compared to its three month average trading volume of 4.36M. The Cambridge Massachusetts 02142 based company has been outperforming the biotechnology companies by -0.1433% for last three months and its recent losses have pulled the stock down -22.29% YTD, versus the biotechnology industry which is up 1.51% for the same period. The RSI of 28.64 indicates the stock is oversold at the current levels, buy for now.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.